Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Monday, December 22, 2025
Celularity’s $10 Million Debt Financing
Friday, December 19, 2025
Kodiak’s $184 Million Public Offering
Mirum’s $69 Million Private Placement
IN8bio’s $40 Million Private Placement
Cue’s $10 Million Public Offering
BioMarin’s $4.8 Billion Acquisition of Amicus
GeoVax’s $3 Million Public Offering
Thursday, December 18, 2025
Kodiak’s $184 Million Public Offering
Syremis’s $165 Million Series A
Atavistik’S $120 Million Series B
Syneron’s $100 Million Series A and A+
Orum’s $100 Million Equity Investment
CAMP4’D $30 Million Public Offering
Rezubio’s $20 Million Series A
Amphix’s $12 Million Seed Round
Biodexa’s $10 Million Public Offering
Lixte’s $4 Million Registered Direct Offering
Wednesday, December 17, 2025
Ambros’s $125 Million Series A
Kyverna’s $100 Million Public Offering
Alvotech’s $100 Million Debt Financing
Aeovian’s $55 Million Series B
FibroBiologics’s $2 Million Registered Direct Offering
MAIA’s $1 Million Private Placement
Tuesday, December 16, 2025
Immunome’s $400 Million Public Offering
Ambros’s $125 Million Series A
Akari’s $5 Million Private Placement
Monday, December 15, 2025
Jade’s $45 Million Private Placement
Friday, December 12, 2025
Contineum’s $90 Million Public Offering
GRI Bio’s $8 Million Public Offering
Enveric’s $3 Million Warrant Exercise
Thursday, December 11, 2025
Terns’s $748Million Public Offering
Immunovant’s $550 Million Public Offering
Dyne’s $403 Million Public Offering
Prolynx’s $70 Million Series A
DISCO’s $42 Million Seed Round
Citius’s $18 Million Registered Direct Offering
Faron’s $12 Million Debt Financing
Allegria’s $5 Million Seed Round
Wednesday, December 10, 2025
BlossomHill’s $84 million Series B
PsiThera’s $48 Million Series A…More
EpilepsyGTx’s $33 Million Series A
Allonia’s $20 Million Series A
Moleculin’s $7 Million Warrant Exercise
Bioxodes’s $6 Million Series A
Tuesday, December 9, 2025
Kymera’s $602 Million Public Offering
Immix’s $100 Million Public Offering
EpilepsyGTx’s $33 Million Series A
TuHURA’s $16 Million Registered Direct Offering
Aprea’s $3 Million Private Placement
Monday, December 8, 2025
Structure’s $500 Million Public Offering
Wave Life Sciences’ $250 Million Public Offering
Vera’s $200 Million Public Offering
Fulcrum’s $150 Million Public Offering
SanegeneBio’s $100 Million Series B
Pan Cancer T’s $12 Million Venture Financing
Convergen’s $10 Million Seed Round
Sunday, December 7, 2025
Friday, December 5, 2025
Capricor’s $150 Million Public Offering
Immatics’s $125 Million Public Offering
Medicus’s $5 Million Warrant Exercise
Thursday, December 4, 2025
Denali’s $275 Million Royalty Financing
Crescent’s $185 Million Private Placement
Protara’s $75 Million Public Offering
SciNeuro’s $53 Million Equity Investment
KALA’s $10 Million Registered Direct Offering
Wednesday, December 3, 2025
TRIANA’s $120 Million Series B
Juvenity’s $20 Million Venture Financing
Auxilius’s $4 Million Series A
Tuesday, December 2, 2025
Belite’s $350 Million Public Offering
Pasithea’s $60 Million Public Offering
Kazia’s $50 Million Private Placement
Axoltis’s $21 Million Series A
Monday, December 1, 2025
Protego’s $130 Million Series B
Circular’s $15 Million Series A
Wednesday, November 26, 2025
Cormorant’s $400 Million Fund Raise
Tempest’s $8 Million Registered Direct Offering
Adial’s $3 Million Warrant Exercise
Tuesday, November 25, 2025
Phrontline’s $60 Million Pre-A+
In coordination with an executive placement firm that is independent and unaffiliated with Collabrity, Inc., we may coordinate with executive(s) who are sourced by that firm and also independent and unaffiliated with Collabrity, Inc.: “Collabrity Executive(s)” does not imply an employment or independent contractor relationship with Collabrity, Inc.
Securities offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity Inc. is not a registered broker-dealer, and Finalis Securities LLC and Collabrity Inc. are separate, unaffiliated entities. Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck